Laddar...
Pembrolizumab in the treatment of locally advanced or metastatic urothelial carcinoma: clinical trial evidence and experience
The treatment of advanced urothelial carcinoma (UC) has dramatically changed with the advent of immune checkpoint inhibitors that disrupt the T-cell inhibitory interaction between the programmed cell death (PD)-1 receptor and its ligand (PD-L1). Pembrolizumab, a highly specific, monoclonal antibody...
Sparad:
| I publikationen: | Ther Adv Urol |
|---|---|
| Huvudupphovsmän: | , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
SAGE Publications
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6452591/ https://ncbi.nlm.nih.gov/pubmed/31057668 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756287219839285 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|